https://www.ox.ac.uk/news/2023-03-22-any-type-hormonal-contraceptive-may-increase-risk-breast-cancer-0 Skip to main content Home Home * Admissions + Undergraduate + Graduate + Continuing education * Research + Engage with us + Support for researchers + Using research to engage + Recognition * News & Events + Events + Features + Oxford profiles + Oxford and coronavirus + Ukraine + News releases for journalists + Filming in Oxford + Find An Expert * About + Organisation + Facts and figures + Oxford people + Oxford Access + International Oxford + Building Our Future + Jobs + Niu Jin Da Xue Search [ ] [Search] News & Events * Events + Regular events in the University Year + University Events Office * Features * Oxford profiles * Oxford and coronavirus * Ukraine * News releases for journalists * Filming in Oxford * Find An Expert Any type of hormonal contraceptive may increase risk of breast cancer Any type of hormonal contraceptive may increase risk of breast cancer Image credit: Shutterstock Published 22 Mar 2023 Share This Tweet Share on Facebook Share on LinkedIn Share on Reddit HomeNewsAny type of hormonal contraceptive may increase risk of breast cancer Any type of hormonal contraceptive may increase risk of breast cancer CancerHealthMedical SciencesResearch An analysis of data by researchers at Oxford Population Health's Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine. Previous studies have shown that use of the combined contraceptive pill, which combines oestrogen and progestogen, is associated with a small increase in the risk of developing breast cancer that declines after stopping use. Use of progestogen-only contraceptives has increased substantially in recent years, but information on their association with breast cancer risk was limited. In 2020, there were almost as many prescriptions issued in England for progestogen-only oral contraceptives as there were for combined oral contraceptives. The researchers analysed data from 9,498 women who developed invasive breast cancer between ages 20 to 49 and 18,171 closely-matched women without breast cancer who acted as controls. The data were collected by the Clinical Practice Research Datalink (CPRD). 44% of women with breast cancer and 39% of women without breast cancer included in the study had a prescription for a hormonal contraceptive an average of three years before diagnosis, around half of whom were last prescribed a progestogen-only contraceptive. The data were used to calculate the strength of the association between use of each type of hormonal contraceptive and breast cancer risk. These calculations were then adjusted to take into account established risk factors such as body mass index (BMI), number of recorded births, and the time since a woman's last birth. The researchers combined the CPRD results on oral contraceptive use with those from other previously published studies to estimate absolute excess risks, meaning the additional number of women who would be expected to develop breast cancer in those who used oral contraceptives compared to those who did not. Key findings: * In the CPRD data, there was a significant increase in risk of breast cancer associated with hormonal contraceptive use, regardless of whether the contraceptive last prescribed was a combined (oestrogen and progestogen) oral preparation (23%, OR=1.23 95% CI 1.14-1.32), a progestogen-only oral preparation (26%, OR=1.26 95% CI 1.16-1.37), an injected progestogen (25%, OR=1.25 95% CI 1.07-1.45), or a progestogen-releasing intra-uterine device (32%, OR=1.32 95% CI 1.17-1.49); * In the CPRD data, the increased risk of breast cancer associated with oral contraceptive use declined after stopping use. The increased risks were: last prescribed within the last year (33%, OR= 1.33 95% CI 1.23-1.44); last prescribed one-four years ago (17%, OR= 1.17 95% CI 1.07-1.29); last prescribed five or more years ago (15%, OR=1.15 95% CI 1.04-1.28); * When the findings for progestogen-only contraceptives were combined with previously published studies, there was an increased risk of breast cancer in current and recent users of all four types of progestogen-only preparations: oral (29%, OR=1.29, 95% CI 1.21-1.37), injected (18%, OR=1.18, 95% CI 1.07-1.30), implanted (28%, OR=1.28, 95% CI 1.08-1.51), and intra-uterine devices (21%, OR=1.21, 95% CI 1.14-1.28); * The researchers estimated that the absolute excess risk of developing breast cancer over a 15-year period in women with five years use of oral contraceptives ranged from eight in 100,000 women for use from age 16 to 20, to 265 in 100,000 for use from age 35 to 39. Kirstin Pirie, statistical programmer at Oxford Population Health, and one of the lead authors, said: 'The findings suggest that current or recent use of all types of progestogen-only contraceptives is associated with a slight increase in breast cancer risk, similar to that associated with use of combined oral contraceptives. Given that a person's underlying risk of developing breast cancer increases with advancing age, the absolute excess risk of breast cancer associated with either type of oral contraceptive will be smaller in women who use it at younger ages. These excess risks must, however, be viewed in the context of the well-established benefits of contraceptive use in women's reproductive years.' The researchers also note that although these findings provide evidence about the short-term associations between hormonal contraceptives and breast cancer risk, they do not provide information regarding longer-term associations, or the impact of total duration of contraceptive use on breast cancer risk, since information on a woman's prescription record prior to joining a participating GP practice would not have been available within the CPRD database. The study, 'Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis ', can be read in PLOS Medicine. The study was funded through core funding provided to the Cancer Epidemiology Unit by Cancer Research UK. Subscribe to News Latest * A pair of hands wearing latex gloves handles crop plants in a field. Image credit: Shutterstock. Oxford biologists comment on new Genetic Technology Act 24 Mar 2023 * New study finds nearly one in five people in the UK find everyday sounds intolerableWhat's your sound barrier? New study finds nearly one in five people in the UK find everyday sounds intolerable 23 Mar 2023 * New research shows how cultural transmission shapes the evolution of musicNew research shows how cultural transmission shapes the evolution of music 22 Mar 2023 * Any type of hormonal contraceptive may increase risk of breast cancerAny type of hormonal contraceptive may increase risk of breast cancer 22 Mar 2023 * Crowd of people on a streetStudy shows viewing self-harm images online and in social media usually causes harm 21 Mar 2023 DISCOVER MORE * Support Oxford's research * Partner with Oxford on research * Study at Oxford * Research jobs at Oxford ALL NEWS You can view all news or browse by category All news Share This Tweet Share on Facebook Share on LinkedIn Share on Reddit Connect with us * iTunes * YouTube * Facebook * Twitter * LinkedIn * Weibo * Instagram * Medium * The Conversation Information About * Oxford University * Strategic plan * Oxford's research * Course fees and funding * Libraries * Museums and collections * Open days * Oxford glossary * Freedom of speech statement * Statement on Modern Slavery * Data privacy / GDPR * Sport at Oxford * Conferences at Oxford * Niu Jin Da Xue Information For * Prospective undergraduates * Prospective graduate students * Prospective Continuing Education students * Prospective online/distance learning students * Current Oxford students * Current Oxford staff * Oxford residents/Community * Visitors/Tourists * Media * Alumni * Teachers * Parliamentarians * Businesses/Partnerships Quick Links * Any questions? * Jobs and vacancies * Term dates * Map * Nexus365 email * Giving to Oxford * (c) University of Oxford 2023 * Contact us * About this site * Legal * Privacy policy * Cookie settings * Accessibility Statement *